Maximilian Diehn
Radiation oncologist who showed a blood test can detect leftover lung cancer months before scans.
Physician-scientist who co-developed CAPP-Seq with Ash Alizadeh and demonstrated ctDNA-based minimal residual disease detection after curative lung cancer treatment. Studies radiation biology and personalised radiotherapy.
| Title | Journal | Year |
|---|---|---|
| Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling | Cancer Discovery | 2017 |
| Integrating genomic features for non-invasive early lung cancer detection | Nature | 2020 |
Pages like this
not linked directly; found by shared links- PersonAsh A. Alizadeh
Shares Stanford Health Care / Stanford Cancer Institute, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- CompanyPersonalis (Tempus)
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeaHPV circulating tumour DNA to guide cervical cancer therapy
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeaBlunt the inflammation that wakes sleeping cancer cells
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Non-small-cell lung cancer.
- InstitutionHealthCare Global Enterprises
Shares SBRT / SABR (stereotactic radiotherapy), Liquid biopsy (ctDNA), Non-small-cell lung cancer.
- IdeaTake the blood test, and give the drug, at the right time of day
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- IdeaA test to tell true oligometastatic disease from hidden widespread spread
Shares SBRT / SABR (stereotactic radiotherapy), MRD / molecular residual disease testing, Liquid biopsy (ctDNA), Non-small-cell lung cancer.
- IdeaKill drug-tolerant persisters through ferroptosis
Shares Stanford Health Care / Stanford Cancer Institute, SBRT / SABR (stereotactic radiotherapy), Liquid biopsy (ctDNA), Non-small-cell lung cancer.